ALLEGRA HIVES Drug Patent Profile
✉ Email this page to a colleague
When do Allegra Hives patents expire, and when can generic versions of Allegra Hives launch?
Allegra Hives is a drug marketed by Chattem Sanofi and is included in one NDA.
The generic ingredient in ALLEGRA HIVES is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and one suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Allegra Hives
A generic version of ALLEGRA HIVES was approved as fexofenadine hydrochloride by TEVA on September 1st, 2005.
Summary for ALLEGRA HIVES
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 127 |
Clinical Trials: | 35 |
Patent Applications: | 1,698 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ALLEGRA HIVES at DailyMed |
Recent Clinical Trials for ALLEGRA HIVES
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, San Francisco | Early Phase 1 |
Food and Drug Administration (FDA) | Early Phase 1 |
University of Alabama at Birmingham | Phase 2 |
Pharmacology for ALLEGRA HIVES
Drug Class | Histamine-1 Receptor Antagonist |
Mechanism of Action | Histamine H1 Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ALLEGRA HIVES
US Patents and Regulatory Information for ALLEGRA HIVES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chattem Sanofi | ALLEGRA HIVES | fexofenadine hydrochloride | TABLET;ORAL | 020872-008 | Jan 24, 2011 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Chattem Sanofi | ALLEGRA HIVES | fexofenadine hydrochloride | TABLET;ORAL | 020872-009 | Jan 24, 2011 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALLEGRA HIVES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chattem Sanofi | ALLEGRA HIVES | fexofenadine hydrochloride | TABLET;ORAL | 020872-008 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
Chattem Sanofi | ALLEGRA HIVES | fexofenadine hydrochloride | TABLET;ORAL | 020872-008 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
Chattem Sanofi | ALLEGRA HIVES | fexofenadine hydrochloride | TABLET;ORAL | 020872-008 | Jan 24, 2011 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALLEGRA HIVES
See the table below for patents covering ALLEGRA HIVES around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Sweden | 448726 | PIPERIDINDERIVAT | ⤷ Try a Trial |
Japan | 2002255936 | FORM III ANTIHISTAMINIC PIPERIDINE DERIVATIVE AND METHOD FOR PREPARING THE SAME | ⤷ Try a Trial |
Australia | 3973493 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |